JP2025106233A5 - - Google Patents

Info

Publication number
JP2025106233A5
JP2025106233A5 JP2025028631A JP2025028631A JP2025106233A5 JP 2025106233 A5 JP2025106233 A5 JP 2025106233A5 JP 2025028631 A JP2025028631 A JP 2025028631A JP 2025028631 A JP2025028631 A JP 2025028631A JP 2025106233 A5 JP2025106233 A5 JP 2025106233A5
Authority
JP
Japan
Prior art keywords
human
fusion protein
mutein
cells
regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025028631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025106233A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/046202 external-priority patent/WO2021030602A1/en
Application filed filed Critical
Publication of JP2025106233A publication Critical patent/JP2025106233A/ja
Publication of JP2025106233A5 publication Critical patent/JP2025106233A5/ja
Pending legal-status Critical Current

Links

JP2025028631A 2019-08-13 2025-02-26 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 Pending JP2025106233A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962886283P 2019-08-13 2019-08-13
US62/886,283 2019-08-13
PCT/US2020/046202 WO2021030602A1 (en) 2019-08-13 2020-08-13 Interleukin-2 muteins for the expansion of t-regulatory cells
JP2022508523A JP2022544236A (ja) 2019-08-13 2020-08-13 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022508523A Division JP2022544236A (ja) 2019-08-13 2020-08-13 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Publications (2)

Publication Number Publication Date
JP2025106233A JP2025106233A (ja) 2025-07-15
JP2025106233A5 true JP2025106233A5 (enExample) 2025-08-21

Family

ID=72291110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022508523A Pending JP2022544236A (ja) 2019-08-13 2020-08-13 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
JP2025028631A Pending JP2025106233A (ja) 2019-08-13 2025-02-26 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022508523A Pending JP2022544236A (ja) 2019-08-13 2020-08-13 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Country Status (20)

Country Link
US (1) US20220289807A1 (enExample)
EP (2) EP4385573A3 (enExample)
JP (2) JP2022544236A (enExample)
KR (1) KR20220044577A (enExample)
CN (1) CN114555634B (enExample)
AR (1) AR119769A1 (enExample)
AU (1) AU2020328038B2 (enExample)
BR (1) BR112022002666A2 (enExample)
CA (1) CA3150441A1 (enExample)
CL (3) CL2022000355A1 (enExample)
CO (1) CO2022002818A2 (enExample)
CR (1) CR20220111A (enExample)
IL (1) IL290433A (enExample)
JO (1) JOP20220036A1 (enExample)
MX (1) MX2022001866A (enExample)
PE (1) PE20220706A1 (enExample)
PH (1) PH12022550326A1 (enExample)
TW (1) TW202120534A (enExample)
UY (1) UY38836A (enExample)
WO (1) WO2021030602A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002272A2 (pt) 2017-08-03 2020-07-28 Synthorx, Inc. conjugados de citocina para o tratamento de doenças autoimunes
JP7636323B2 (ja) 2018-11-08 2025-02-26 シンソークス， インコーポレイテッド インターロイキン１０コンジュゲートおよびその使用
AU2020337869A1 (en) 2019-08-23 2022-03-03 Synthorx, Inc. IL-15 conjugates and uses thereof
JP7758662B2 (ja) 2019-09-10 2025-10-22 シンソークス， インコーポレイテッド Ｉｌ－２コンジュゲートおよび自己免疫疾患を治療するための使用方法
US20240352084A1 (en) 2021-07-22 2024-10-24 University Of Dundee Therapeutic muteins
CN115487292B (zh) * 2022-09-28 2025-01-21 河北师范大学 一种治疗糖尿病的联合用药物及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US233A (en) 1837-06-14 Improvement in plows
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
US6388066B1 (en) 1998-09-29 2002-05-14 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
EP1395669B1 (en) 2001-01-26 2009-07-22 Selexis S.A. Matrix attachment regions and methods for use thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2545755A1 (en) 2003-11-12 2005-05-26 Schering Corporation Plasmid system for multigene expression
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
JP2013511281A (ja) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
CN117659160A (zh) * 2015-09-11 2024-03-08 小利兰·斯坦福大学托管委员会 生物相关正交细胞因子/受体对
KR20250133490A (ko) * 2016-05-04 2025-09-05 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
IL293471A (en) * 2019-12-17 2022-08-01 Amgen Inc Dual interleukin-2 / tnf receptor agonist for use in medicine

Similar Documents

Publication Publication Date Title
JP2025106233A5 (enExample)
JP2023134534A5 (enExample)
JP2018512151A5 (enExample)
Bjorkman et al. Structure of the human class I histocompatibility antigen, HLA-A2
CN100488984C (zh) 降低融合蛋白的免疫原性
CN103201284B (zh) 用于癌症和慢性感染的治疗的具有激动剂活性的衍生自il-2的多肽
JPH10502249A (ja) 免疫調節剤
AU2002324249B2 (en) Interleukin-18 mutants, their production and use
HU216310B (hu) Eljárás citokinszintézis inhibitorfaktor (CSIF), CSIF-aktivitású polipeptidek és CSIF-antagonisták, valamint ezeket tartalmazó gyógyszerkészítmények előállítására
PT585681E (pt) Utilizacao do receptor de il-4 para terapia, profilaxia e diagnostico de doencas infecciosas
US20040072291A1 (en) Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
JP2004529633A (ja) 低減された免疫原性を有する修飾されたヒトインターフェロンベータ
JP2004535777A (ja) 低減された免疫原性を有する修飾された顆粒球マクロファージコロニー刺激因子（ｇｍ−ｃｓｆ）
JP2004520836A (ja) 低減された免疫原性を有する修飾されたプロタミン
KR20030081480A (ko) 감소된 면역원성을 갖는 변형된 모양체 신경자극 인자（ｃｎｔｆ）
JP4156671B2 (ja) Ｔ細胞抗原受容体ペプチド
US20040063634A1 (en) Modified kertinocyte growth factor (kgf) with reduced immunogenicity
JP2004527243A (ja) 低減された免疫原性を有する修飾された顆粒球コロニー刺激因子（ｇ−ｃｓｆ）
Swiderski et al. Molecular cloning, sequencing, and expression of equine interleukin-6
Wei et al. Molecular cloning and sequence analysis of interferon-gamma and interleukin-6 from Tibetan macaque (Macaca thibetana)
EP0256042A1 (en) Interleukin
Bello-Rivero et al. Construction, purification, and characterization of a chimeric TH1 antagonist
JP3049613B2 (ja) 組換えマウスｉｌ―６レセプターの製造方法
JP3028847B2 (ja) マウスｇｐ１３０蛋白質
Stern et al. Purification to homogeneity and amino acid sequence analysis of a receptor protein for interleukin 1